Bioxytran (OTCQB: BIXT) discloses officer Mike Sheikh’s termination

Rhea-AI Filing Summary

Bioxytran, Inc. reported that effective December 29, 2025, Mike Sheikh was terminated as an officer of the company. The filing does not describe his specific role or responsibilities, but notes that his separation is formally effective on that date. In a letter dated December 31, 2025, Mike Sheikh is contesting the reason for his dismissal, and this dispute is identified as a factor in determining any severance benefits. The report does not provide additional financial information or changes to the company’s operations beyond this leadership change.

false 0001445815 0001445815 2025-12-29 2025-12-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 29, 2025

BIOXYTRAN, INC.

(Exact Name of Registrant as Specified in Charter)

Nevada		001-35027		26-2797630
(State or Other Jurisdiction		(Commission		(IRS Employer
of Incorporation)		File Number)		Identification Number)

75 Second Ave, Suite 605, Needham, MA		02494
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code 617-454-1199

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001		BIXT		OTCQB

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Effective as of December 29, 2025, Mike Sheikh was terminated as an Officer of Bioxytran, Inc. (the “Company”).

In a letter dated December 31, 2025, Mike Sheikh is contesting the reason for his dismissal, which is a factor in determining severance benefits, if any.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit #		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BIOXYTRAN, INC.
	By:	/s/ David Platt, Ph.D.
		David Platt, Ph.D., its Chief Executive Officer
Date December 31, 2025

FAQ

What did Bioxytran, Inc. (BIXT) disclose in this 8-K filing?

Bioxytran, Inc. disclosed that effective December 29, 2025, Mike Sheikh was terminated as an officer of the company. The filing also notes that he is contesting the reason for his dismissal in a letter dated December 31, 2025, which may affect his severance benefits.

Who was terminated from Bioxytran, Inc. (BIXT) and when did it take effect?

The filing states that Mike Sheikh was terminated as an officer of Bioxytran, Inc., effective December 29, 2025. No further details about his specific position are provided.

Is Mike Sheikh disputing his termination from Bioxytran, Inc. (BIXT)?

Yes. The report notes that in a letter dated December 31, 2025, Mike Sheikh is contesting the reason for his dismissal. This dispute is identified as a factor in determining his severance benefits, if any.

Does the Bioxytran, Inc. (BIXT) 8-K discuss severance benefits for Mike Sheikh?

The filing indicates that the reason for dismissal, which Mike Sheikh is contesting, is a factor in determining severance benefits, if any. It does not specify whether any severance has been granted or its amount.

Does this Bioxytran, Inc. (BIXT) filing include financial results or earnings data?

No financial statements or earnings data are included. The 8-K focuses on the termination of officer Mike Sheikh and his contesting of the dismissal reason as it relates to potential severance.

Who signed the Bioxytran, Inc. (BIXT) 8-K related to the officer termination?

The report was signed on behalf of Bioxytran, Inc. by David Platt, Ph.D., the company’s Chief Executive Officer, dated December 31, 2025.